Welcome to the e-CCO Library Archive!
Pregnancy outcomes after exposure to certolizumab pegol: Results from safety surveillance
U. Mahadevan1, S. Vermeire2, D.C. Wolf3, F. Forger4, J.J. Cush5, A. Golembesky6, L. Shaughnessy6, D. De Cuyper7, S. Abbas8, M.E.B. Clowse9, 1UCSF Medical Center, San Francisco, United States, 2University Hospital Gasthuisberg, Division of Gastroenterology, Leuven, Belgium, 3Atlanta Gastroenterology Associates, Atlanta, United States, 4University of Bern, Department of Rheumatology and Clinical Immunology and Allergology, Bern, Switzerland, 5Baylor Research Institute and Baylor University Medical Center, Dallas, United States, 6UCB Pharma, Raleigh, United States, 7UCB Pharma, Brussels, Belgium, 8UCB Pharma, Paris, France, 9Duke University Medical Center, Rheumatology, Durham, United States
Allogeneic bone marrow-derived mesenchymal stromal stem cells for the treatment of refractory perianal Crohn fistulas: a dose-escalating placebo-controlled study
Molendijk I1, Bonsing BA2, Roelofs H3, Peeters KCMJ2, Wasser MNJM4, Dijkstra G5, van der Woude CJ6, Veenendaal RA1, Zwaginga JJ3, Verspaget HW*1, Fibbe WE3, van der Meulen-de Jong AE1, Hommes DW1,5.
1Dept. Gastroenterology and Hepatology, 2Dept. Surgery, 3Dept. Immunohematology and Blood Transfusion and 4Dept. of Radiology, Leiden University Medical Center, Leiden, The Netherlands. 5Dept. Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, The Netherlands. 6Dep. Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands. 7Div. Digestive Diseases, University of California Los Angeles, USA.
High rate of IBD in younger age groups among 1 degree relatives to IBD affected cases, a population-based cohort study 1977–2011
F. Trier Moller1,2, V. Andersen3, T. Jess2, 1Southern University of Denmark, Institute for Regional Health Research, Odense, Denmark, 2Statens Serum Institut, Department of Epidemiology Research, Copenhagen, Denmark, 3Southern University of Denmark, Institute for Regional Health Research – SHS, Odense, Denmark
Description of colorectal cancers detected in the Dutch population based IBD-SL cohort
T. van den Heuvel*1, 2, C. le Clerq2, S. Jeuring1, 2, R. Marx2, M. Zeegers3, 4, D. Jonkers1, 2, W. Hameeteman2, L. Oostenbrug5, M. Romberg-Camps6, A. Masclee1, 2, S. Sanduleanu2, M. Pierik1, 2
1Maastricht University Medical Centre+, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht, Netherlands, 2Maastricht University Medical Centre+, Internal Medicine - Division Gastroenterology-Hepatology, Maastricht, Netherlands, 3University of Birmingham, Public Health, Epidemiology and Biostatistics, Birmingham, United Kingdom, 4Maastricht University Medical Center+, Complex Genetics, Cluster of Genetics and Cell Biology, Maastricht, Netherlands, 5Atrium Medical Center, Internal Medicine and Gastroenterology, Heerlen, Netherlands, 6Orbis Medical Centre, Gastroenterology and Hepatology, Sittard-Geleen, Netherlands
Work related problems and impaired productivity in patients with inflammatory bowel diseases (IBD)
A. Zand, W.K. Van Deen, C.H. Ha, E. Kane, J.M. Choi, B.E. Roth, A. Centeno, E. Esrailian, D.W. Hommes, UCLA Center for Inflammatory Bowel Diseases, Division of Digestive Diseases, University of California, Los Angeles, Los Angeles, United States
Increased cancer risk in Dutch Crohn's disease patients: Results from the population based IBD-SL cohort
T. van den Heuvel*1, 2, D. Wintjens2, S. Jeuring1, 2, W. Hameeteman2, L. Oostenbrug3, M. Romberg-Camps4, A. Masclee1, 2, M. Zeegers5, 6, D. Jonkers1, 2, M. Pierik1, 2
1Maastricht University Medical Centre+, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht, Netherlands, 2Maastricht University Medical Centre+, Internal Medicine - Division Gastroenterology-Hepatology, Maastricht, Netherlands, 3Atrium Medical Center, Internal Medicine and Gastroenterology, Heerlen, Netherlands, 4Orbis Medical Centre, Gastroenterology and Hepatology, Sittard-Geleen, Netherlands, 5University of Birmingham, Public Health, Epidemiology and Biostatistics, Birmingham, United Kingdom, 6Maastricht University Medical Center+, Complex Genetics, Cluster of Genetics and Cell Biology, Maastricht, Netherlands
Work disability in patients with inflammatory bowel diseases. Final report from two referral centers
M. Mandel1, A. Balint2, B. Lovasz1, L. Kiss1, P.A. Golovics1, Z. Vegh1, K. Farkas2, T. Molnar2, A. Mohas1, B. Szilagyi1, P. Lakatos1, 1Semmelweis University, 1st Department of Medicine, Budapest, Hungary, 2University of Szeged, 1st Department of Medicine, Szeged, Hungary
Survival in inflammatory bowel disease related colorectal cancer
A. Askari*1, S. Nachiappan1, J. Murphy2, S. Mills3, T. Athanasiou4, O. Faiz1
1St. Mark's Hospital, Imperial College London, Surgical Epidemiology, Trials & Outcomes Centre (SETCO), London, United Kingdom, 2St. Mark's Hospital, Surgery, London, United Kingdom, 3Chelsea & Westminster Hospital, Surgery, London, United Kingdom, 4St. Mary's Hospital, Imperial College London, Department of Cardiovascular Medicine, London, United Kingdom
Development of red flags for early referral of adults with symptoms and signs suggestive of Crohn's disease: an IOIBD initiative
S. Danese1, G. Fiorino1, L. Peyrin-Biroulet2, P.L. Lakatos3, J.Y. Mary4, G. D'Haens5, L. Moja6,7, A. D'Hoore8, J. Panes9, W. Reinisch10, W.J. Sandborn11, S. Travis12, S. Vermeire13, J.F. Colombel14, 1Humanitas Research Hospital, IBD Center, Rozzano, Milan, Italy, 2Nancy University Hospital, Université de Lorraine, Gastroenterology and Hepatology, Vandoeuvre-les-Nancy, France, 3Semmelweis University, 1st Department of Medicine, Budapest, Hungary, 4Saint Louis Hospital, INSERM U717, Paris, France, 5Academic Medical Center, Department of Gastroenterology, Amsterdam, Netherlands, 6IRCCS Galeazzi Orthopedic Institute, Unit of Clinical Epidemiology, Milan, Italy, 7University of Milan, Department of Biomedical Sciences for Health, Milan, Italy, 8University Hospitals Leuven, Department of Abdominal Surgery, Leuven, Belgium, 9Hospital Clinic de Barcelona, IDIBAPS and CIBERehd, Gastroenterology Unit, Barcelona, Spain, 10AKH, Medizinische Universität, Klinische Abt. Gastroenterologie & Hepatologie, Wien, Italy, 11University of California, San Diego, Inflammatory Bowel Disese Center, Division of Gastroenterology, La Jolla, United States, 12John Radcliffe Hospital, Translational Gastroenterology Unit, Oxford, United Kingdom, 13Katholieke Universiteit and University Hospital Gasthuisberg, Division of Gastroenterology, Leuven, Belgium, 14Hemsley Inflammatory Bowel Disease Center, Icahn Medical School of Medicine at Mount Sinai, New-York, United States
Efficacy and safety of retreatment with vedolizumab in patients with ulcerative colitis
B.E. Sands*1, I. Shafran2, F.A. Farraye3, A.S. Cheifetz4, B. Abhyankar5, S. Sankoh6, M. Smyth7
1Icahn School of Medicine at Mount Sinai Hospital, Gastroenterology, New York, United States, 2Shafran Gastroenterology Center, Gastroenterology, Winter Park, FL, United States, 3Boston Medical Center, Gastroenterology, Boston, MA, United States, 4Beth Israel Deaconess Medical Center, Medicine, Boston, MA, United States, 5Takeda Global Research and Development Centre (Europe) Ltd., Clinical Science, London, United Kingdom, 6Takeda Pharmaceuticals International Co., Statistics, Cambridge, Massachusetts, United States, 7Takeda Global Research and Development Centre (Europe) Ltd., Medical, London, United Kingdom
Assessment of wall inflammation and fibrosis in Crohn's disease and its correlation with bowel sonography and MRI-enterography
A. Rispo1, P.P. Mainenti2, F.P. D'Armiento3, A. Testa1, M. Rea1, D. Musto1, M. Diaferia1, L. Bucci4, G. Pesce5, F. Castiglione1, 1AOU Policlinico Federico II of Naples, Gastroenterology, Naples, Italy, 2AOU Policlinico Federico II of Naples, Radiology, Naples, Italy, 3AOU Policlinico Federico II of Naples, Pathology, Naples, Italy, 4AOU Policlinico Federico II of Naples, Colorectal Surgery, Naples, Italy, 5AOU Policlinico Federico II of Naples, General Surgery, Naples, Italy
Ustekinumab efficacy and safety in Crohn's disease patients refractory to conventional and anti-TNF therapy: a multicenter retrospective experience.
P. Wils*1, Y. Bouhnik2, B. Flourie3, H. Brixi4, J. Cosnes5, M. Allez6, B. Duclos7, P. Michetti8, J.-C. Grimaud9, G. Bommelaer10, A. Amiot11, M. Fumery12, J. Filippi13, V. Abitbol14, B. Coffin15, M. Simon16, D. Laharie17, B. Pariente1
1CHU de Lille, Department of Gastroenterology, Lille, France, 2Beaujon Hospital, Gastroenterology Unit, Clichy, France, 3Centre Hospitalier Lyon-Sud, Service d'Hépato-gastro-entérologie, Lyon, France, 4CHU de Reims, Gastroenterologie, Reims, France, 5University Hospital of Saint Antoine, APHP, Gastroenterology, Paris, France, 6APHP, Hopital Saint Louis, Department of Gastroenterology, Paris, France, 7Université de Strasbourg, Gastroenterology, Strasbourg, France, 8University Hospital Lausanne, Division of Gastroenterology & Hepatology,, Lausanne, Switzerland, 9Hôpital Nord, Gastroenterology Unit, Marseille, France, 10CHU de Clermont-Ferrand, Department of Gastroenterology, Clermont-Ferrand, France, 11Hospital Henri-Mondor, Department of Gastroenterology, Creteil, France, 12Amiens University Hospital, Gastroenterology, Amiens, France, 13CHU de Nice, Department of Gastroenterology, Nice, France, 14Cochin University Hospital, Gastroenterology, Paris, France, 15Hopital Louis-Mourier, Gastroenterologie, Colombes, France, 16Institut Mutualiste Montsouris , Gastroenterology , Paris, France, 17CHU de Bordeaux, Gastroenterology, Pessac, France
Feasibility, precision and reproducibility of MR enterography for detection of inflammation in Crohn's Disease in a multicenter clinical trial
J. Rimola1, W.J. Sandborn2, P. Higgins3, A. Coimbra4, T. Lu4, P. Rutgeerts5, D. Luca4, D. Bruining6, S. Vermeire5, J. Panes7, C. Santillan8, M. Al-Hawary9, J. Fidler10, D. Vanbeckevoort11, R. Vanslembrouck11, L. Peyrin-Biroulet12, V. Laurent13, S. O'Byrne4, A. de Crespigny4, 1Hospital Clínic de Barcelona, Radiology Department, Barcelona, Spain, 2University of California San Diego, Division of Gastroenterology, La Jolla, United States, 3University of Michigan, Internal Medicine – Gastroenterology, Ann Arbor, MI, United States, 4Genentech, Research and Early Development, South San Francisco, United States, 5KU Leuven, Division of Gastroenterology, Leuven, Belgium, 6Mayo Clinic, Gastroenterology, Rochester, United States, 7Hospital Clínic Barcelona, Department of Gastroenterology, Barcelona, Spain, 8University of California San Diego, Radiology, San Diego, United States, 9University of Michigan, Radiology, Ann Arbor, United States, 10Mayo Clinic, Radiology, Rochester, United States, 11Biomedical MRI, KU Leuven Department of Imaging and Pathology, Leuven, Belgium, 12Nancy University Hospital, Université de Lorraine, Gastroenterology and Hepatology, Vandoeuvre-les-Nancy, France, 13Brabois Hospital, Gastroenterology, Vandoeuvre les Nancy, France
GLPG0974, an FFA2 antagonist, in ulcerative colitis: efficacy and safety in a multicenter proof-of-concept study
S. Vermeire*1, V. Kojecký2, V. Knoflícek3, W. Reinisch4, T. Van Kaem5, F. Namour6, J. Beetens5, F. Vanhoutte5
1University Hospital Leuven, Gastroenterology, Leuven, Belgium, 2Krajska nemocnice T Bati, Interni klinika IPVZ, Zlin, Czech Republic, 3Nemocnice Znojmo, Internal Medicine, Znojmo, Czech Republic, 4McMaster University, Gastroenterology, Hamilton, Canada, 5Galapagos NV, Development, Mechelen, Belgium, 6Galapagos SASU, Development, Romainville, France
A multicenter study to evaluate magnetic resonance enterography (MRE) for selection of Crohn's disease patients for inclusion into a therapeutic clinical trial
P. Higgins1, W.J. Sandborn2, J. Rimola3, T. Lu4, A. Coimbra4, P. Rutgeerts5, D. Luca4, D. Bruining6, S. Vermeire5, C. Santillan7, M. Al-Hawary8, J. Fidler9, D. Vanbeckevoort10, R. Vanslembrouck10, L. Peyrin-Biroulet11, V. Laurent12, A. de Crespigny4, S. O'Byrne4, J. Panes13, 1University of Michigan, Internal Medicine – Gastroenterology, Ann Arbor, MI, United States, 2University of California San Diego, Division of Gastroenterology, La Jolla, United States, 3Hospital Clínic de Barcelona, Radiology Department, Barcelona, Spain, 4Genentech, Research and Early Development, South San Francisco, United States, 5KU Leuven, Division of Gastroenterology, Leuven, Belgium, 6Mayo Clinic, Gastroenterology, Rochester, United States, 7University of California San Diego, Radiology, San Diego, United States, 8University of Michigan, Radiology, Ann Arbor, United States, 9Mayo Clinic, Radiology, Rochester, United States, 10Biomedical MRI, KU Leuven Department of Imaging and Pathology, Leuven, Belgium, 11Nancy University Hospital, Université de Lorraine, Gastroenterology and Hepatology, Vandoeuvre-les-Nancy, France, 12Brabois Hospital, Gastroenterology, Vandoeuvre les Nancy, France, 13Hospital Clínic Barcelona, Department of Gastroenterology, Barcelona, Spain
Phase I study of intraperitoneal administration of autologous tolerogenic dendritic cells for refractory Crohn's disease.
A. Jauregui-Amezaga*1, R. Cabezón2, A. Ramírez-Morros2, C. España2, J. Rimola3, C. Bru3, S. Pinó-Donnay2, M. Gallego2, M.C. Masamunt2, I. Ordás2, M. Lozano4, J. Cid4, J. Panés2, D. Benítez-Ribas2, E. Ricart2
1University Hospitals Leuven, Gastroenterology - Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 2Hospital Clínic de Barcelona, Gastroenterology, Barcelona, Spain, 3Hospital Clínic de Barcelona, Radiology, Barcelona, Spain, 4Hospital Clínic de Barcelona, Hemotherapy and Hemostasis, Barcelona, Spain
Clinical impact and safety of capsule endoscopy in patients with established Crohn's disease – a multicenter cross-sectional study
U. Kopylov1, A. Nemeth2, A. Koulaouzidis3, R. Makins4, W. Afif5, G. Wild1, A. Bitton1, G.W. Johansson6, T. Bessissow1, E. Toth6, E.G. Seidman1, 1McGill University Health Center, Gastroenterology, Montreal, Canada, 2Skåne University Hospital, Lund University, Department of Gastroenterology, Malmo, Sweden, 3Royal Infirmary of Edinburgh, Endoscopy Unit, Centre for Liver and Digestive Disorders, Edinburgh, United Kingdom, 4Gloucestershire Hospitals NHS Foundation Trust, Gastroenterology, London, United Kingdom, 5McGill University, Division of Gastroenterology, Montreal Quebec, Canada, 6University Hospital Skane, Gastroenterology-Hepatology Division, Malmö, Sweden
Fistula treatment with adipose derived mesenchymal stem cells - prospective study on experimental model of perianal Crohn's disease
O. Ryska*1, Z. Serclova1, O. Mestak2, E. Matouskova3, P. Vesely2, I. Mrazova4
1Horovice Hospital, Department of Surgery, Horovice, Czech Republic, 2Bulovka Hospital, Plastic Surgery, Prague, Czech Republic, 33rd Medical Faculty Charles University, Department of Burns Medicine, Prague, Czech Republic, 4Institute for Clinical and Experimental Medicine, Centrum of Experimental Medicine, Prague, Czech Republic
Evaluation of site versus central assessment of endoscopies in Crohn's disease: Comparison using data from EXTEND
P. Rutgeerts1, W. Reinisch2, W.J. Sandborn3, G. D'Haens4, J.-F. Colombel5, J. Petersson6, Q. Zhou6, R.B. Thakkar6, 1KU Leuven, Division of Gastroenterology, Leuven, Belgium, 2McMaster University, Department of Medicine, Hamilton, Canada, 3University of California, San Diego, Division of Gastroenterology, La Jolla, United States, 4Academic Medical Center, Department of Gastroenterology, Amsterdam, Netherlands, 5Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States, 6AbbVie Inc, GPRD, North Chicago, United States
Efficacy and safety of anti-TNF therapy for inflammatory bowel disease (IBD) in liver transplant recipients for primary sclerosing cholangitis (PSC): a multicenter experience.
R. Combes*1, R. Altwegg1, D. Laharie2, V. De Ledinghen2, S. Radenne3, F. Conti4, O. Chazouilleres4, C. Duvoux5, L. Peyrin-Biroulet6, J. Dumortier7, V. Leroy8, X. Treton9, F. Durand9, S. Dharancy10, M. Nachury10, F. Goutorbe11, G. Lamblin11, G.-P. Pageaux1
1University Hospital of St Eloi, Departement of Hepatology and Gastroenterology, Montpellier, France, 2University hospital of Bordeaux, Haut-Leveque Hospital, Hepato-Gastroenterology, Bordeaux, France, 3Hospices Civils de Lyon, Croix-Rousse, Hepato-Gastroenterology, Lyon, France, 4University Hospital of Saint Antoine, APHP, Hepato-Gastroenterology, Paris, France, 5University Hospital of Henri Mondor, APHP, Hepato-Gastroenterology, Creteil, France, 6University Hospital of Nancy, Gastroenterology, Nancy, France, 7Hospices Civils de Lyon, Edouard Hériot Hospital, Hepato-Gastroenterology, Lyon, France, 8University Hospital of Grenoble, Hepato-Gastroenterology, Grenoble, France, 9University hospital of Beaujon, APHP, Gastroenterology, Clichy, France, 10University hospital of Lille, Hepato-Gastroenterology, Lille, France, 11University Hospital of Clermont-Ferrand, Hepato-Gastroenterology, Clermont-Ferrand, France